Therapeutics Related News

Synthetic Biology and Immunotherapy to Bring More Effective Cell Therapies for Cancer

For years, the foundations of cancer treatment were chemotherapy, surgery, and radiation therapy. But over the past several years, progress with therapies that collect and use a patient’s own immune cells to attack tumors (in other words, immunotherapy) have greatly [...]

By | September 22nd, 2017|BioPharma & Healthcare, News, Therapeutics|

Meet Jacob Glanville, a scientist and entrepreneur pioneering the next generation of biomedicine

This week we interviewed Jacob Glanville, a computational immunoengineer who co-founded Distributed Bio, a company focused on applying computationally-guided immunoengineering methods to enable a new generation of monoclonal antibody discovery and universal vaccine design. He applies his hybrid expertise in [...]

By | September 19th, 2017|BioPharma & Healthcare, News, Therapeutics|

Berkeley Lights Announces Strategic Project with Bayer Focused on Cell Line Development and Antibody Discovery

Beacon™ OptoFluidic Platform to Automate Workflows for Greater Efficiencies Emeryville, CA – September 12, 2017 – Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, today announced a strategic project with Bayer AG, Germany (Bayer), [...]

By | September 18th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services

Cambridge, UK, 18 September 2017: Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces that it has expanded its functional genomic screening portfolio to include first-to-market CRISPRi (interference) and CRISPRa [...]

By | September 18th, 2017|BioPharma & Healthcare, News, Therapeutics|

LifeMine Therapeutics Launches with $55 Million Series A Financing

New Company Hacks Evolutionary Code to Discover Disruptively Innovative Drugs; Backed by Powerful Investor Syndicate BOSTON, Sept. 18, 2017 /PRNewswire/ -- LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite [...]

By | September 18th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

A $200M Dollar Mistake: Why It’s Best To Be Patient With CRISPR

Every now and then, there’s a report that totally changes the scope of a field. When it’s good, it can feel like the promised land is right around the corner. But when it’s bad, it feels like the sky is [...]

By | September 16th, 2017|BioPharma & Healthcare, News, Therapeutics|